CORT Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 39.28%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 83.47%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $129.51 which suggests that it could grow by 8.98%. Given that Corcept Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Corcept Therapeutics, Inc. has a beta of 0.431, which suggesting that the stock is 56.889% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.206%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.64% to investors and pays a quarterly dividend of $0.79 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 84.23x while Gilead Sciences, Inc.'s PE ratio is 18.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 11.89x versus 5.14x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 2.63%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 83.47%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $46.67 which suggests that it could grow by 13.74%. Given that Corcept Therapeutics, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Hims & Hers Health, Inc..

Corcept Therapeutics, Inc. has a beta of 0.431, which suggesting that the stock is 56.889% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.200, suggesting its more volatile than the S&P 500 by 119.991%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 84.23x while Hims & Hers Health, Inc.'s PE ratio is 75.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 11.89x versus 4.61x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of -49.65%. Corcept Therapeutics, Inc.'s return on equity of 16% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -364.55%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 83.47%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Corcept Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Corcept Therapeutics, Inc. has a beta of 0.431, which suggesting that the stock is 56.889% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.667%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 84.23x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 11.89x versus 1.11x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 34.76%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 83.47%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $479.92 which suggests that it could grow by 17.21%. Given that Corcept Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Corcept Therapeutics, Inc. has a beta of 0.431, which suggesting that the stock is 56.889% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.334%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 84.23x while Vertex Pharmaceuticals, Inc.'s PE ratio is 28.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 11.89x versus 9.04x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.